IP Library Granted Patent US 9,884,136
Granted Patent B2
US 9,884,136 · App. 15/434,339 · Granted Feb 6, 2018

Compositions for treating biofilms and methods for using same

Inventors: George Rodeheaver (Charlottesville, VA); Adam Katz (Charlottesville, VA)
Assignee: PluroGen Therapeutics, Inc.
A61L15/44A61K31/635A61K31/765A61K33/38A61L2300/104A61L2300/216A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,136
App. No.
15/434,339
Filed
Feb 16, 2017
Granted
Feb 6, 2018
Kind
B2
Art Unit
1619
USPC
424/445
Abstract

Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.

Claims (15)

1. A method for treating a chronic wound comprising applying a composition to the chronic wound comprising about 30 w/w % to about 80 w/w % surface active agent selected from the group consisting of poloxamer 127, poloxamer 188, poloxamer 237, poloxamer 335, poloxamer 407, and combinations thereof and about 1% or less by weight of the composition of an antimicrobial agent.

2. The method of claim 1 , wherein the antimicrobial agent is selected from the group consisting of an antibacterial, an antifungal, an antiviral or a combination thereof.

3. The method of claim 1 , wherein the antimicrobial agent is selected from the group consisting of furaltadone, furazolium chloride, nifuradene, nifuratel, nifurfoline, nifurpirinol, nifurprazine, nifurtoinol, nitrofurantoin, furazolidone, 2-(methoxymethyl)-5-nitrofuran, nidroxyzone, nifuroxime, nifurazide, nitrofurazone, nystatin, polymyxin, silver sulfadiazine, nanocrystalline silver, ionic silver, silver salts, iodine, benzalkonium chloride, alcohol, hydrogen peroxide, chlorhexidine, honey and combinations thereof.

4. The method of claim 1 , wherein the antimicrobial agent is silver sulfadiazine.

5. The method of claim 1 , wherein the surface active agent is poloxamer 188.

6. The method of claim 1 , wherein the chronic wound is selected from the group consisting of chronic venous ulcers, diabetic ulcers, arterial ulcers, pressure ulcers, decubitis ulcers, radiation ulcers, traumatic wounds, non-healing wounds, and combinations thereof.

7. A method for treating a chronic wound comprising contacting the chronic wound with a dressing having a composition comprising about 30 w/w % to about 80 w/w % surface active agent selected from the group consisting of poloxamer 127, poloxamer 188, poloxamer 237, poloxamer 335, poloxamer 407, and combinations thereof and about 1% or less by weight of the composition of an antimicrobial agent impregnated on a dressing material.

8. The method of claim 7 , wherein the antimicrobial agent is selected from the group consisting of an antibacterial, an antifungal, an antiviral, and combinations thereof.

9. The method of claim 7 , wherein the antimicrobial agent is selected from the group consisting of furaltadone, furazolium chloride, nifuradene, nifuratel, nifurfoline, nifurpirinol, nifurprazine, nifurtoinol, nitrofurantoin, furazolidone, 2-(methoxymethyl)-5-nitrofuran, nidroxyzone, nifuroxime, nifurazide, nitrofurazone, nystatin, polymyxin, silver sulfadiazine, nanocrystalline silver, ionic silver, silver salts, iodine, benzalkonium chloride, alcohol, hydrogen peroxide, chlorhexidine, honey, and combinations thereof.

10. The method of claim 7 , wherein the antimicrobial agent is silver sulfadiazine.

11. The method of claim 7 , wherein the surface active agent is poloxamer 188.

12. The method of claim 7 , wherein the chronic wound is selected from the group consisting of chronic venous ulcers, diabetic ulcers, arterial ulcers, pressure ulcers, decubitis ulcers, radiation ulcers, traumatic wounds, non-healing wounds, and combinations thereof.

13. The method of claim 7 , wherein contacting comprises applying the dressing to the chronic wound.

14. A method for treating a chronic wound comprising applying to the chronic wound a composition comprising about 30 w/w % to about 80 w/w % of poloxamer 188 and up to 1% by weight of the composition of silver sulfadiazine.

15. The method of claim 14 , wherein the chronic wound is selected from the group consisting of chronic venous ulcers, diabetic ulcers, arterial ulcers, pressure ulcers, decubitis ulcers, radiation ulcers, traumatic wounds, non-healing wounds, and combinations thereof.

Assignments (7)
PATENT SECURITY AGREEMENT Recorded May 28, 2026
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 075643/0462 →
PATENT SECURITY AGREEMENT Recorded Jun 20, 2025
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 071672/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2022
From: PLUROGEN THERAPEUTICS, LLC
To: MEDLINE INDUSTRIES, LP
Reel/Frame 059162/0143 →
SECURITY INTEREST Recorded Oct 21, 2021
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057927/0091 →
SECURITY INTEREST Recorded Oct 21, 2021
From: MEDLINE INDUSTRIES, LP
To: BANK OF AMERICA, N.A.
Reel/Frame 058040/0001 →
QUITCLAIM/TRANSFER Recorded Mar 20, 2018
From: PLUROGEN THERAPEUTICS, INC.
To: PLUROGEN THERAPEUTICS, LLC
Reel/Frame 045657/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2017
From: RODEHEAVER, GEORGE; KATZ, ADAM
To: PLUROGEN THERAPEUTICS, INC.
Reel/Frame 043333/0141 →
Continuity (6)
Continuation 15016191 · Feb 4, 2016
Continuation 14524332 · Oct 27, 2014
Division 13685444 · Nov 26, 2012
Continuation 12033692 · Feb 19, 2008
Provisional Application 60890535 · Feb 19, 2007
Related Publication 20170216480A1 · Aug 3, 2017